Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. [electronic resource]
Producer: 20110929Description: 1108-10 p. digitalISSN:- 1873-5835
- Aged
- Aged, 80 and over
- Anemia -- drug therapy
- Antimetabolites, Antineoplastic -- therapeutic use
- Apoptosis -- drug effects
- Azacitidine -- therapeutic use
- Erythroid Precursor Cells -- drug effects
- Erythropoiesis -- drug effects
- Erythropoietin -- therapeutic use
- Female
- Flow Cytometry
- Humans
- Male
- Middle Aged
- Myelodysplastic Syndromes -- complications
- Prognosis
- bcl-X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.